托法替尼
医学
银屑病
斑块性银屑病
甲氨蝶呤
贾纳斯激酶
Janus激酶抑制剂
临床试验
皮肤病科
发病机制
二苯甲酚
药理学
免疫学
内科学
类风湿性关节炎
细胞因子
作者
Abraham M. Korman,Denise S. Hill,Ali Alikhan,Steven R. Feldman
标识
DOI:10.1586/17512433.2016.1154785
摘要
New treatments for psoriasis have been developed based on increasing knowledge of the underlying pathogenesis of the disease. The development of very safe and highly effective biologics has revolutionized the treatment of moderate-to-severe psoriasis. Biologics are not perfect, however, as they are delivered parenterally, immunogenic, and costly. Small molecule agents, with molecular weights of less than 1 kDa, are being developed and hold the advantage of being administered orally. Tofacitinib is an oral Janus kinase inhibitor that has been developed to disrupt the aberrant JAK-STAT pathway that contributes to the pathogenesis of psoriasis. Phase II and Phase III clinical trial results for tofacitinib are encouraging, demonstrating substantial efficacy and satisfactory safety in the treatment of patients with moderate-to-severe chronic plaque psoriasis. An effective oral treatment without the organ toxicities of methotrexate and cyclosporine, tofacitinib is a promising alternative to biologics in the treatment of moderate-to-severe psoriasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI